Senores Pharmaceuticals' key subsidiary, Havix, has successfully completed its USFDA inspection at its manufacturing facility in Georgia, USA.

The inspection concluded with 3 procedural and minor 483 observations.

Havix is committed to swiftly responding to these observations within 15 days.

This outcome is positive for Senores, as it indicates a largely compliant manufacturing process vital for its US market access and continued operations, minimizing potential future regulatory hurdles.